Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.Although it may seem like it has hit a peak given the stock's slowdown in recent weeks, there could be a huge catalyst upcoming for the business next year. It's one that investors should keep a close eye on because it could send the stock to record highs in 2025.Eli Lilly is a big name in diabetes care and weight loss. Tirzepatide generates billions in revenue for the healthcare company. It is a GLP-1 injectable that is approved for diabetes under the Mounjaro brand and for weight loss under Zepbound. But what investors are really eager to find out is if the company may have a GLP-1 weight loss pill in its portfolio in the near future.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool